Ide-Cel Shows Durable Response in R/R Multiple Myeloma: Larry D. Anderson, Jr, MD, PhD

Video

The hematologist/oncologist from the Harold C. Simmons Comprehensive Cancer Center discussed the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.

This content originally appeared on our sister site, Targeted Oncology.

Targeted Oncology spoke with Larry D. Anderson, Jr, MD, PhD, hematologist/oncologist, Harold C. Simmons Comprehensive Cancer Center and associate professor, Division of Hematology/Oncology, Department of Internal Medicine, UT Southwestern Medical Center, about the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.

Long-term data for idecabtagene vicleucel (ide-cel, bb2121) demonstrated deep and durable remissions in a majority of patients on the trial, according to Anderson. Patients with relapsed/refractory multiple myeloma on this trial had a median of 6 prior lines of therapy. With a median 24.8-month follow-up, the median overall survival on trial was 24.8 months also. For the 128 patients, there was a 73% overall response rate, and the median progression-free survival (PFS) was 8.6 months. Those who received the target dose of 450 million chimeric antigen receptor T cells had a median PFS of 12.2 months.

Anderson says another notable topic was the FDA label for ide-cel requires patients to have 4 prior lines of therapy while the trial only required 3 prior lines of therapy. One of the study analyses looked at efficacy for patients who received 3 prior lines versus 4 or more. There was not a significant difference in outcomes for these 2 groups.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Tia DiTommaso, PhD, the senior director of preclinical pharmacology Arbor Biotechnologies, and John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute.
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine.
© 2025 MJH Life Sciences

All rights reserved.